CA Patent

CA2310632A1 — Use of .delta.5-androstene-3.beta.-ol-7,17-dione in the treatment of lupus erythematosus

Assigned to Humanetics Corp · Expires 1999-05-27 · 27y expired

What this patent protects

Lupus erythematosus can be treated by administering therapeutic amounts of .DELTA.5-androstene-3.beta.-ol-7,17-dione and metabolizable precursors thereof, such as .DELTA.5-androstene-3b-acetoxy-7,17-dione, which are readily metabolized in vivo to .DELTA.5-androstene-3.beta.-ol-7,…

USPTO Abstract

Lupus erythematosus can be treated by administering therapeutic amounts of .DELTA.5-androstene-3.beta.-ol-7,17-dione and metabolizable precursors thereof, such as .DELTA.5-androstene-3b-acetoxy-7,17-dione, which are readily metabolized in vivo to .DELTA.5-androstene-3.beta.-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.

Drugs covered by this patent

Patent Metadata

Patent number
CA2310632A1
Jurisdiction
CA
Classification
—
Expires
1999-05-27
Drug substance claim
No
Drug product claim
No
Assignee
Humanetics Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.